Clinical Faculty

Dr. Burow received his B.S. in Biology in 1994 at the University of Southern Mississippi. He completed his Ph.D. in 1998 at Tulane University from the Interdisciplinary Graduate Program in Molecular and Cellular Biology. Dr. Burow carried out his post-doctoral studies with Dr. John McLachlan at the Tulane/Xavier Center for Bioenvironmental Research.

Dr. Burow was appointed in 2000 as a Research Assistant Professor in the Department of Pharmacology. In 2002, Dr. Burow accepted a position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine. In 2007 Dr. Burow was promoted to Associate Professor of Medicine with tenure.

Dr. Burow's primary research interests focus on understanding the molecular mechanisms that control estrogen receptor mediated gene expression and anti-estrogen resistance in breast carcinoma cells in the progression of breast carcinoma to a hormone independent, drug resistant and metastatic phenotype. Through this research Dr. Burow has developed a second research direction focused on the development of novel anti-cancer agents based upon naturally occurring plant phytoallexins known as glyceollins.

Selected Publications:

Tilghman SL, Zimmermann MC, Boué SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MS, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME. Glyceollin I, a novel anti-estrogenic phytoalexin isolated from activated soy. Journal Pharmacology & Experimental Therapeutics (2009). Accepted for publication.

Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Lacey M, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Research and Treatment (2009). Accepted for publication.

Payton-Stewart F, Schoene NW, Kim YS, Burow ME, Cleveland TE, Boue SM, Wang TT. Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP. Mol Carcinogenesis 2009; 48(9):862-871.

Boue SM, Cleveland TE, Carter-Wientjes C, Shih BY, Bhatnagar D, McLachlan JA, Burow ME. Phytoalexin-Enriched Functional Foods. Journal of Agriculture and Food Chemistry 2009; 57(7):2614-2622.

Boue SM, Tilghman SL, Elliott S, Zimmerman MC, Williams K, Payton-Stewart F, Miraflor A, Carter-Wientjes C, Shih BY, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 2009; 150(5):2446-2453.

Bratton MR, Frigo DE, Vigh KA, Fan D, Wadsworth S, McLachlan JA, Burow ME. Organochlorine mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis 2009; 30(1):106-113.

Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Research 2008; 10(6):R105.

Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt P, Beckman BS, McLachlan JA, Cleveland TE, Burow ME. Antiestrogenic Glyceollins Suppress Human Breast and Ovarian Carcinoma Tumorigenesis. Clinical Cancer Research 2006; 12(23):7159-7164.

Duong, BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME. AKT regulation of ER-beta transcriptional activity in breast cancer. Cancer Research 2006; 66(17):8373-8381.

Frigo DE, Basu A, Simpson EN, Weldon CB, Dugan CB, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME. The p38 MAPK Stimulates Estrogen-Mediated Transcription and Proliferation Through the Phosphorylation and Potentiation of the p160 Coactivator Glucocorticoid receptor interacting protein 1. Molecular Endocrinology 2006; 20(5): 971-983.